|Budget Amount *help
¥2,100,000 (Direct Cost : ¥2,100,000)
Fiscal Year 1997 : ¥900,000 (Direct Cost : ¥900,000)
Fiscal Year 1996 : ¥600,000 (Direct Cost : ¥600,000)
Fiscal Year 1995 : ¥600,000 (Direct Cost : ¥600,000)
Since we developed transgenic mice expressing HGF in liver (G.Shiota et al.Hepatology 19,962-972,1994), we have studied anti-tumor effect of HGF by using transgenic mice. First, we studied metastatic potentials of hepatocellular carcinoma (HCC) cells in chimeric mice of HGF transgenic and nude. Second, we have developed 2 kinds of double transgenic mice of HGF with TGFalpha and c-myc, and have evaluated effect of HGF on TGFalpha-or c-myc-induced hepatocarcinogenesis.
1. Metastatic potential of HCC cells, such as HUH7, Hep3B and FaO cells, via portal vein was greatly suppressed in HGF/nude chimeric mice compared to nude control mice (81% vs.35%, p<0.05). 2. Double transgenic mice of TGFalpha and HGF developed HCC in 33% of mice, whereas TGFalpha mice developed HCC in 60% of mice. 3. Although c-myc mice developed adenoma and HCC in 92% and 58% of mice, HGF/c-myc double transgenic mice did 33% and 0%, respectively.